Biovie Inc. financial data

Symbol
BIVI on Nasdaq
Industry
Pharmaceutical Preparations
Location
680 W Nye Lane, Suite 201, Carson City, Nevada
State of incorporation
Nevada
Fiscal year end
June 30
Former names
NANOANTIBIOTICS, INC. (to 7/22/2016)
Latest financial report
10-Q - Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 199 % -51%
Debt-to-equity 127 % -6.12%
Return On Assets -129 % +11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61M shares +68.2%
Common Stock, Shares, Outstanding 61M shares +68.7%
Entity Public Float 86M USD +268%
Common Stock, Value, Issued 6.12K USD +69.3%
Weighted Average Number of Shares Outstanding, Basic 44.8M shares +26.8%
Weighted Average Number of Shares Outstanding, Diluted 44.8M shares +26.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29.3M USD -4.94%
Operating Income (Loss) -38.4M USD +11.6%
Nonoperating Income (Expense) -336K USD +73.5%
Net Income (Loss) Attributable to Parent -36.3M USD +26.3%
Earnings Per Share, Basic -0.95 USD/shares +42.1%
Earnings Per Share, Diluted -0.95 USD/shares +42.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.4M USD -2.96%
Other Assets, Current 285K USD +565%
Assets, Current 30.5M USD -30.7%
Operating Lease, Right-of-Use Asset 422K USD +366%
Intangible Assets, Net (Excluding Goodwill) 465K USD -33%
Goodwill 346K USD 0%
Other Assets, Noncurrent 4.56K USD
Assets 31.8M USD -29.7%
Accounts Payable, Current 4.41M USD -8.87%
Liabilities, Current 12.5M USD -22%
Operating Lease, Liability, Noncurrent 366K USD +573%
Other Liabilities, Noncurrent 48.4K USD
Liabilities 12.8M USD -45.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 177K USD
Retained Earnings (Accumulated Deficit) -329M USD -12.7%
Stockholders' Equity Attributable to Parent 18.9M USD -12.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 26.1M USD +62.3%
Liabilities and Equity 31.8M USD -29.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.2M USD -32.1%
Net Cash Provided by (Used in) Financing Activities -594K USD -105%
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 61M shares +68.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.4M USD -2.96%
Interest Paid, Excluding Capitalized Interest, Operating Activities 529K USD +12.5%
Deferred Tax Assets, Valuation Allowance 13.6M USD +69.5%
Operating Lease, Liability 424K USD +333%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.2M USD +40.4%
Lessee, Operating Lease, Liability, to be Paid 604K USD +451%
Operating Lease, Liability, Current 57.1K USD +31.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 118K USD +126%
Lessee, Operating Lease, Liability, to be Paid, Year One 29.1K USD +125%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +37.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.38K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 122K USD +173%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 126K USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 229K USD 0%
Depreciation, Depletion and Amortization 57.3K USD 0%
Interest Expense 3.56M USD -13.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%